ArticleFrontiers in medicine2022
Global, regional, and national burden of uterine fibroids in the last 30 years: Estimates from the 1990 to 2019 Global Burden of Disease Study.
Article in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Preoperative medical therapy before surgery for uterine fibroids.The Cochrane database of systematic reviews · 2025Pooled it
- Safety and efficacy of vilaprisan in Japanese women with fibroids: The Phase 3 ASTEROID 8 trial.Women's health (London, England)Trial
- Prevalence and associated risk factors of uterine fibroids in the Kingdom of Eswatini.South African family practice : official journal of the South African Academy of Family Practice/Primary Care · 2026Article
- Global Burden of Premenstrual Syndrome and Uterine Fibroids in Women of Reproductive Age (1990-2023) and Projections to 2050: An Analysis of the Global Burden of Disease Study 2023.Health science reports · 2026Article
- Cost analysis of hospital-based symptomatic uterine fibroids in the kingdom of Eswatini: A prevalence-based cost-of-illness study.PloS one · 2026Article
- Article
- The stem bark decoction of Myrianthus arboreus P. Beauv. (Cecropiaceae) shows anti-uterine leiomyoma effects in Wistar rat.Reproduction & fertility · 2025Article
- Minimally Invasive Myomectomy: A Systematic Review of Techniques, Challenges, and Fertility Outcomes.Cureus · 2025Review
- Epidemiological features of uterine fibroid-associated imaging changes in Chinese women of reproductive age: a retrospective study.BMJ open · 2025Observational
- Detection of exon2-MED12 mutations in uterine leiomyomas from Syrian patients.Scientific reports · 2025Article
- The Role of Nanomedicine in Benign Gynecologic Disorders.Molecules (Basel, Switzerland) · 2024Review
- Ureter adhesion to the fibroid.BMJ case reports · 2023Article
- Evidence-Based Approach for Secondary Prevention of Uterine Fibroids (The ESCAPE Approach).International journal of molecular sciences · 2023Review
- Population-based study of the reproductive risk factors for transvaginal ultrasound diagnosed uterine fibroids in Nigerian women.Scientific reports · 2023Article
- Uterine Fibroids: A Podcast on Patient and Physician Perspectives on Medical Management and a New Medical Therapy (Relugolix Combination Therapy).Advances in therapy · 2023Article
- Review
- Risk of uterine leiomyomata with menstrual and reproductive factors in premenopausal women: Korea nurses' health study.BMC women's health · 2023Article
- Prevalence and clinical significance of co-existing mutations inFrontiers in reproductive health · 2023Article
- The long-term trend of uterine fibroid burden in China from 1990 to 2019: A Joinpoint and Age-Period-Cohort study.Frontiers in physiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To study specific information on trends in incidence, mortality, disability-adjusted life years (DALY) and the corresponding trends among five sociodemographic index regions, 21 regions, and 204 countries for decision-making, which would enable policymakers to distribute limited resources and devise policies more rationally. Methods: Data on uterine fibroids (UNs) from 1990 to 2019, including incidence, mortality, and DALYs, were obtained from the 2019 Global Burden of Disease Study. An estimated annual percentage change (EAPC) was calculated to assess morbidity, mortality, and DALY trends. Results: The incident cases of UFs increased from 5,769,658 (95%UI, 7,634,3995-4,274,824) incidences in 1990 to 9,643,336 (95%UI, 7,178,053-12,714,741) incidences in 2017, and the age-standardized incidence rate was steady at 225.67/100,000 persons (95%UI, 167.33-298.87) in 1990 to 241.18/100,000 persons (95%UI, 179,45-318.02) in 2019. The incidence ratio in the high sociodemographic index (SDI) region showed a unimodal distribution, with peaks in 2005. Between 2009 and 2017, the age-standardized death rate of UFs declined globally, especially in low-SDI and low-middle SDI regions. In contrast with 860,619 DALYs (95%UI, 473,067-1,505,289) in 1990, the number of DALYs was 1,378,497 (95%UI, 710,915-2,475,244) in 2019, which had increased significantly, whereas the age-standardized DALY rate decreased expressively with an EAPC of -1.93 (95%CI, from -2.16 to -1.71). Conclusion: The global burden of UFs increased between 1990 and 2019, and the incidences and DALYs increased prominently worldwide, while the deaths from UFs had no evident growth. Lower SDI regions carried an incremental burden of UFs, while disease reduction was observed in higher SDI regions. It is high time we paid attention to the underprivileged regional quality of life and health protection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.